PDCD1 and neoplasm: Immune checkpoint blockade (ICB) with PD-1 antibody or PD-L1 antibody can block the binding between PD-1 and PD-L1, and allow the T cells to destroy tumor cells (Hu et al., 2021b; Jiang et al., 2021; Archilla-Ortega et al., 2022).